Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer

Anne Rodallec , Jean-Michel Brunel , Sarah Giacometti (1) , Helene Maccario , Florian Correard , Eric Mas , Caroline Orneto , Ariel Savina , Fanny Bouquet , Bruno Lacarelle (1) , Joseph Ciccolini (1) , Raphaelle Fanciullino (1)

1 CRCM - Centre de Recherche en Cancérologie de Marseille

Background: Trastuzumab plus docetaxel is a mainstay to treat HER2-positive breast cancers. However, developing nanoparticles could help to improve the efficacy/toxicity balance of this doublet by improving drug trafficking and delivery to tumors. This project aimed to develop an immunoliposome in breast cancer, combining docetaxel encapsulated in a stealth liposome engrafted with trastuzumab, and comparing its performances on human breast cancer cell lines with standard combination of docetaxel plus trastuzumab. Methods: Several strategies to engraft trastuzumab to pegylated liposomes were tested. Immunoliposomes made of natural (antibody nanoconjugate-1 [ANC-1]) and synthetic lipids (ANC-2) were synthesized using standard thin film method and compared in size, morphology, docetaxel encapsulation, trastuzumab engraftment rates and stability. Antiproliferative activity was tested on human breast cancer models ranging from almost negative (MDA-MB-231), positive (MDA-MB-453) to overexpressing (SKBR3) HER2. Finally, cell uptake of ANC-1 was studied by electronic microscopy. Results: ANC-1 showed a greater docetaxel encapsulation rate (73%+/- 6% vs 53%+/- 4%) and longer stability (up to 1 week) as compared with ANC-2. Both ANC presented particle size <= 150 nm and showed similar or higher in vitro antiproliferative activities than standard treatment, ANC-1 performing better than ANC-2. The IC50s, for docetaxel combined to free trastuzumab were 8.7 +/- 4, 2 +/- 0.7 and 6 +/- 2 nM with M DA-MB-231, M DA-M B-453 and SKBR3, respectively. The IC50s for ANC-1 were 2.5 +/- 1, 1.8 +/- 0.6 and 3.4 +/- 0.8 nM and for ANC-2 were 1.8 +/- 0.3 nM, 2.8 +/- 0.8 nM and 6.8 +/- 1.8 nM with MDA-MB-231, MDA-MB-453 and SKBR3, respectively. Cellular uptake appeared to depend on HER2 expression, the higher the expression, the higher the uptake. Conclusion: In vitro results suggest that higher antiproliferative efficacy and efficient drug delivery can be achieved in breast cancer models using nanoparticles.

Domaines: Sciences du Vivant [q-bio]

Anne Rodallec, Jean-Michel Brunel, Sarah Giacometti, Helene Maccario, Florian Correard, et al.. Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer. International Journal of Nanomedicine, 2018, 13, pp.3451-3465. ⟨10.2147/IJN.S162454⟩. ⟨hal-02143590⟩